Chevy Chase Trust Holdings Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,675,303 shares of the company’s stock after selling 33,705 shares during the quarter. Johnson & Johnson accounts for about 1.7% of Chevy Chase Trust Holdings Inc.’s portfolio, making the stock its 4th biggest holding. Chevy Chase Trust Holdings Inc. owned 0.10% of Johnson & Johnson worth $353,917,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Lenox Wealth Advisors Inc. grew its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the period. Lbmc Investment Advisors LLC grew its stake in Johnson & Johnson by 0.4% in the 1st quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after acquiring an additional 14 shares during the period. RB Capital Management LLC grew its stake in Johnson & Johnson by 0.4% in the 1st quarter. RB Capital Management LLC now owns 5,559 shares of the company’s stock valued at $692,000 after acquiring an additional 24 shares during the period. Keel Point LLC grew its stake in Johnson & Johnson by 0.4% in the 1st quarter. Keel Point LLC now owns 6,402 shares of the company’s stock valued at $797,000 after acquiring an additional 24 shares during the period. Finally, Berson & Corrado Investment Advisors LLC grew its stake in Johnson & Johnson by 0.8% in the 2nd quarter. Berson & Corrado Investment Advisors LLC now owns 2,859 shares of the company’s stock valued at $378,000 after acquiring an additional 24 shares during the period. 65.90% of the stock is currently owned by hedge funds and other institutional investors.

In related news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) is Chevy Chase Trust Holdings Inc.’s 4th Largest Position” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/11/johnson-johnson-jnj-is-chevy-chase-trust-holdings-inc-s-4th-largest-position.html.

A number of equities research analysts recently issued reports on JNJ shares. Cowen and Company reissued an “outperform” rating and issued a $143.00 price target on shares of Johnson & Johnson in a research note on Tuesday, June 13th. Royal Bank Of Canada reissued a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 15th. Jefferies Group LLC reissued a “hold” rating and issued a $140.00 price target on shares of Johnson & Johnson in a research note on Friday, June 16th. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $136.02.

Johnson & Johnson (NYSE:JNJ) traded up 2.02% on Wednesday, hitting $136.60. The stock had a trading volume of 3,921,067 shares. The stock has a market cap of $366.63 billion, a price-to-earnings ratio of 22.96 and a beta of 0.78. The stock’s 50 day moving average is $132.27 and its 200 day moving average is $130.03. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.74 earnings per share. Analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 56.76%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.